Antipodes Partners awarded

2026 Fund Manager of the Year, Australia

Morningstar Awards 2026 © Morningstar, Inc. All Rights Reserved.

Insights: Asian Equities outlook

The Antipodes Asia Fund delivered strong returns over the past year. But with returns highly concentrated in a handful of large-cap tech stocks, the more compelling story may be what’s still to come. John Stavliotis breaks down what drove performance, why he believes the emerging markets cycle has further to run, and where Antipodes is finding value in some of Asia’s most overlooked markets. 

 

Transcript

Welcome back to another Antipodes Insights video. Today our focus will be on the Antipodes Asia Fund. I’m joined by John Stavliotis, portfolio manager for the strategy. Welcome, John. Thanks, Jonathan.

We’re again in 2025 and we’ve seen strong performance in the strategy. John, can you give us a recap of what happened?

The Asia Fund was up 20% for the year. Asia outperformed global indices and Australian indices, but one of the interesting things we saw in Asia, China and EM more broadly was the concentration of returns. It was circa 30% of stocks in the index that beat the index – the most concentrated return series in the last 25 years.
I put that down to this being the first year of Asia outperformance in some time, and it’s really global investors coming in and buying the large caps and buying the thematics. That’s evident if you break down the returns – the tech hardware sector accounted for 61% of the return of the benchmark. So it’s concentration at the sector level as well, and if you look at counties as well there’s a similar thematic going on.
With our value-based process, that made it quite difficult to keep up, and we underperformed the benchmark given that the tech hardware sector and some of the high valuation stocks were leaders in the benchmark. However, we’ve started to see that turn in the last 6 months and we’ve generated alpha in the last 6 months as returns have started to broaden.

If you look at our positioning, we’ve got a weighting towards some of the structural winners where we see value, and also some of the cyclical stocks that are showing deep value but importantly are showing quite resilient earnings performance and will benefit from any continued recovery in the economies we’re expecting going forward. So if we do see a broadening of returns in Asia and an improvement in the underlying economies, we think the portfolio will perform quite well.

Looking back at history, we’ve seen a prolonged period of emerging markets broadly underperforming developed markets, which has obviously disappointed investors even though they’ve seen attractive valuations. Now we’ve seen strong returns in the last couple of years relative to developed market equities. Is this an opportunity for investors to participate, or have they missed the boat – especially in light of our process?

We think there are a number of indicators pointing to a turn into a longer period of outperformance for EM and Asia. Some of the indicators we look at include US dollar weakness – the US dollar has significantly outperformed other currencies over the last 15 years and there are signs of that topping out. We’re also seeing interest rate normalisation in the US, and importantly global growth is recovering relative to the US. What’s driven that developed market outperformance really comes down to US exceptionalism.

If we do see global growth catching up with the US – and we’re seeing that through improvements in commodity prices and strong fiscal positions in emerging market economies – If that growth continues to recover we will see emerging market Asia outperform. An interesting number I like to quote is that the market cap of the Magnificent Seven is over two times the market cap of the MSCI EM Index. A small amount of money coming out of those top companies will have a huge effect on equities in emerging markets and Asia, and that’s what will drive a longer period of outperformance.

Ex-China, we’ve also participated in a number of other countries where we think markets are undervalued. One of those is Indonesia, where we have a structural overweight – though it hasn’t necessarily paid off in the short term. Can you talk us through what’s happening at a macro level in Indonesia and how we participate at the stock level?

Indonesia was the worst performing market in Asia last year, and our overweight here would be quite controversial relative to other global investors – it is very underowned at this point. To clarify, we went overweight in the second half of last year, taking advantage of that underperformance.

To explain how we arrived at this overweight – a change in leadership saw the Prabowo government come in and change the rhetoric in Indonesia quite a bit. What was previously focused on investment shifted to a focus on consumption, trying to drive GDP growth through consumption and elevating the middle of the economy, which had been suffering for a number of years. That led to a lack of confidence in the economy, and a pullback in spending by government bodies and government-related companies in that initial stage of the new government – and we could see that in the data.

We also had MSCI threaten to lower the weightings towards Indonesia, which scared off a lot of global investors. We’ve done a lot of work to analyse what needs to be done, and we’re seeing that the government and regulators in Indonesia are meeting the demands of MSCI, which will remove that liquidity threat. Valuations in Indonesia are at lows we haven’t seen since the global financial crisis (GFC) or the Asian crisis – the average index valuation is at the 25th percentile of where the index has traded historically. That really creates an opportunity to buy some resilient growth businesses that are actually performing quite well through this period.
Fast forward to when we started to go overweight – the government has begun to set their policies in recent months and actually enact some consumer stimulus. We’ve started to see consumer sentiment figures improve since September last year, continuing to improve all the way into January. We’re also starting to hear improving commentary from some consumer companies. All of these things are pointing to the disruption from the leadership change having found a bottom. And as we talked about earlier, a lower US dollar and lower rates will help address one of the key issues of liquidity in Indonesia – increasing liquidity in the system, which will help drive investment, consumption and equities.

Another focus within Indonesia has been the banking sector, again driven by valuations but also some structural themes – specifically our exposure through Bank Mandiri. John, can you walk us through that?

The Indonesian banking industry is quite attractive. A bit like Australia, it’s controlled by four banks — the top four have circa 50–55% share of loans. Mandiri has about 14–15% share, making it one of the key banks in the industry.
The issue with the banks, and why they’ve traded so cheaply, is a lack of liquidity in the system and a lack of growth in deposits. What that’s meant is that net interest costs have gone up for the banks, and they haven’t been able to grow deposits to drive loan growth. So loan growth has slowed. But there are signs of this starting to improve – we’ve started to see deposit growth pick up in the last quarter, and with a weaker dollar and lower rates, that helps keep liquidity in Indonesia and drive growth in the industry. We’ve also seen the regulator try to stimulate the banks into driving more lending, which is quite positive for this business.

Mandiri is a very high quality bank. It has a return on equity (ROE) of 18% and is now trading at a price-to-book of 1.5 times, which is well below its historical average multiple. When you think about through-cycle growth for the Indonesian banking system or for Mandiri specifically, we think it’s in the low-to-mid teens, which is a high level of growth, especially when you compare Australian banks and where they’re trading relative to ROE and growth. Mandiri really stands out as a very attractive opportunity to increase the size of our postion. And although growth is slower right now, we are being paid to wait – the dividend yield on this stock is currently over 8%. So we’re getting paid to wait until we get back to through-cycle growth, at a very attractive valuation.

Overall, as you can see, Asia provides a very diverse set of opportunities. Performance has been strong in the last year, especially compared to developed market equities as well as Australia. The stories right across the region are very differentiated – not only in China, but also in a very much unloved market like Indonesia, where we’ve taken the opportunity to build a position. That’s how our pragmatic value philosophy really comes to life.

If you have any further questions, please reach out to your Antipodes representative or your representative from Pinnacle Investment Management.

Subscribe to receive the latest news and insights from the Antipodes team

IMPORTANT INFORMATION:
This information has been prepared by Antipodes Partners Limited (‘Antipodes’) (ABN 29 602 042 035, AFSL 481 580) as the Investment manager of the Antipodes China Fund (ARSN 116 380 771) (‘Fund’) and the Antipodes Asia Fund (ARSN 134 226 029) (‘Fund’). Maple-Brown Abbott Limited (“MBAL”) (ABN 73 001 208 564, AFSL 237296), is the Responsible Entity for the Antipodes China and Asia Funds. MBAL is a subsidiary of Antipodes Partners Holdings PTY LTD (ABN 91 602 828 526). This report contains general information only, and does not take into account your investment objectives, financial situation or specific needs. Before making any investment decision, you should seek independent financial advice. This document does not constitute an offer or solicitation by anyone in any jurisdiction. Past performance is not a reliable indicator of future performance. Neither MBA, nor any of its related parties, directors or employees, make any representation or give any guarantee as to the return of capital, performance, any specific rate of return, or the taxation consequences of, any investment.
Any views expressed on individual stocks or other investments, or any forecasts or estimates, are not a recommendation to buy, sell or hold, they are point in time views and may be based on certain assumptions and qualifications not set out in part or in full in this document. Individual stocks referred to may or may not be currently held by the Fund. Information derived from sources is believed to be accurate, however such information has not been independently verified and may be subject to assumptions and qualifications not described in this document. To the extent permitted by law, neither MBA, nor any of its related parties, directors or employees, make any representation or warranty as to the accuracy, completeness, reasonableness or reliability of this information, or accept liability or responsibility for any losses, whether direct, indirect or consequential, relating to, or arising from, the use or reliance on this information. Before making a decision whether to acquire, or to continue to hold an investment in the Fund, investors should obtain and consider the current PDS and Target Market Determination (TMD) or any other relevant disclosure document. For the Fund, the PDS, AIB and TMD are available at www.antipodes.com or by calling 1300 097 995.

Share:

More Posts

Now available on the ASX: the Antipodes Global SMID Active ETF (ASX:MIDS)

X